TRT and Cardiovascular Risk: What the Research Actually Shows

This content is for general information only and is not medical advice. See a licensed physician for your specific situation. This page contains affiliate links; if you make a purchase through one, we may earn a commission at no extra cost to you.

For years, the honest answer to “does TRT raise your risk of a heart attack” was “nobody actually knows for sure” — the evidence conflicted, and no large trial existed to settle it. That changed with a real, large-scale trial. Here’s what it actually found, including the parts that aren’t reassuring.

The Trial That Changed the Evidence Picture

A large, randomized, placebo-controlled trial enrolled over 5,200 men aged 45 to 80, all with existing cardiovascular disease or a high risk of it — specifically the population where a cardiovascular safety question matters most. Half received daily testosterone gel, half received a matching placebo gel, in a double-blind design (neither participants nor researchers knew who got which during the study). This is the kind of study design that actually answers a safety question, rather than the smaller or retrospective studies that produced conflicting signals in the past.

The Reassuring Finding

On the primary question — major adverse cardiovascular events like heart attack, stroke, and cardiovascular death — the trial found no significant difference between the testosterone group and the placebo group. For men with confirmed low testosterone and appropriate medical supervision, this is a genuinely meaningful update: the specific fear that drove a lot of TRT hesitancy for over a decade didn’t hold up under a trial actually designed to test it.

What Wasn’t Reassuring

This is the part that responsible coverage of this trial has to include, not gloss over: the testosterone group did show a real increase in three specific things compared to placebo — non-fatal irregular heart rhythms (arrhythmias), venous thromboembolism (blood clots, typically in the legs or lungs), and bone fractures. None of these were part of the primary cardiovascular-event finding, but they’re real, elevated risks documented in the same trial, not a separate concern pulled from weaker evidence. A trial that clears TRT on one specific question while flagging real risk on others is a more honest, more useful result than either an unqualified “safe” or an unqualified “dangerous.”

What This Actually Means for a Real Decision

If cardiovascular risk was the main thing holding you back from seriously considering TRT, this trial is a legitimate reason to revisit that with your doctor — the evidence genuinely improved. It’s not a reason to skip the conversation about blood clot history, arrhythmia risk, or bone health specifically, since those are the real, elevated risks this same trial surfaced. See our full breakdown of TRT’s benefits and risks for how this fits into the bigger picture, and our guide on what to expect from your first consultation for the questions worth raising with a provider directly.

This Doesn’t Replace Your Own Risk Profile

Trial results describe average outcomes across a large group — they don’t automatically apply to any one individual’s specific risk factors, family history, or existing conditions. If you have a personal or family history of blood clots or arrhythmia, that’s a real, specific conversation to have directly with a physician who knows your full history, not something a general trial result can settle on your behalf. Proper ongoing monitoring — bloodwork that actually tracks hematocrit and other relevant markers, not a one-time prescription and no follow-up — is what actually catches a developing problem early. TRT Nation’s licensed telehealth consultations include that kind of monitoring as part of the process; see our full TRT Nation review for the honest details.